The Experts below are selected from a list of 47718 Experts worldwide ranked by ideXlab platform
Andrew Carr - One of the best experts on this subject based on the ideXlab platform.
-
calcific tendinitis natural history and association with Endocrine disorders
Orthopaedic Proceedings, 2018Co-Authors: Paul Harvie, Pollard Tcb, Andrew CarrAbstract:The purpose of this study was to investigate the association of Endocrine Disease with calcific tendinitis and the effects that such Disease has on its natural history.A retrospective observational cohort study of 102 consecutive patients (125 shoulders) with calcific tendinitis is presented. Seventy-three (71.6 %) female, 29 (28.4 %) male. Compared with population prevalences, significant levels of Endocrine disorders were found in our study cohort. Sixty-six patients (81 shoulders, 62 female (93.9 %), 4 male (6.1 %), mean age 50.3 years) with associated Endocrine Disease were compared with 36 patients (44 shoulders, 11 female (30.6 %), 25 male (69.4 %), mean age 52.4 years) without Endocrine Disease. The Endocrine cohort were significantly younger than the non-Endocrine cohort when symptoms started (mean 40.9 years and 46.9 years respectively, p=0.0026), had significantly longer natural histories (mean 79.7 months compared with 47.1 months, p=0.0015) and a significantly higher proportion underwent opera...
-
calcific tendinitis natural history and association with Endocrine disorders
Journal of Shoulder and Elbow Surgery, 2007Co-Authors: Paul Harvie, T C B Pollard, Andrew CarrAbstract:A retrospective, observational cohort study of 102 consecutive patients (125 shoulders) with calcific tendinitis is presented. Of the patients, 73 (71.6%) were women and 29 (28.4%) were men. Compared with population prevalences, significant levels of Endocrine disorders were found. We compared 66 patients (62 women [93.9%] and 4 men [6.1%]; mean age, 50.3 years) (81 shoulders) with associated Endocrine Disease with 36 patients (11 women [30.6%] and 25 men [69.4%]); mean age, 52.4 years) (44 shoulders) without Endocrine Disease. The Endocrine cohort was significantly younger than the non-Endocrine cohort when symptoms started (mean, 40.9 years and 46.9 years, respectively), had significantly longer natural histories (mean, 79.7 months compared with 47.1 months), and had a significantly higher proportion who underwent operative treatment (46.9% compared with 22.7%). Disorders of thyroid and estrogen metabolism may contribute to calcific tendinitis etiology. Classifying calcific tendinitis into type I (idiopathic) and type II (secondary or Endocrine-related) aids prognosis and management.
-
calcific tendinitis natural history and association with Endocrine disorders
Journal of Bone and Joint Surgery-british Volume, 2005Co-Authors: Paul Harvie, T C B Pollard, Andrew CarrAbstract:The purpose of this study was to investigate the association of Endocrine Disease with calcific tendinitis and the effects that such Disease has on its natural history. A retrospective observational cohort study of 102 consecutive patients (125 shoulders) with calcific tendinitis is presented. Seventy-three (71.6 %) female, 29 (28.4 %) male. Compared with population prevalences, significant levels of Endocrine disorders were found in our study cohort. Sixty-six patients (81 shoulders, 62 female (93.9 %), 4 male (6.1 %), mean age 50.3 years) with associated Endocrine Disease were compared with 36 patients (44 shoulders, 11 female (30.6 %), 25 male (69.4 %), mean age 52.4 years) without Endocrine Disease. The Endocrine cohort were significantly younger than the non-Endocrine cohort when symptoms started (mean 40.9 years and 46.9 years respectively, p=0.0026), had significantly longer natural histories (mean 79.7 months compared with 47.1 months, p=0.0015) and a significantly higher proportion underwent operative treatment (46.9 % compared with 22.7 %, p=0.0014). Disorders of thyroid and oestrogen metabolism may contribute to calcific tendinitis aetiology. Classifying calcific tendinitis into Type I idiopathic and Type II secondary or Endocrine-related aids prognosis and management.
Paul Harvie - One of the best experts on this subject based on the ideXlab platform.
-
calcific tendinitis natural history and association with Endocrine disorders
Orthopaedic Proceedings, 2018Co-Authors: Paul Harvie, Pollard Tcb, Andrew CarrAbstract:The purpose of this study was to investigate the association of Endocrine Disease with calcific tendinitis and the effects that such Disease has on its natural history.A retrospective observational cohort study of 102 consecutive patients (125 shoulders) with calcific tendinitis is presented. Seventy-three (71.6 %) female, 29 (28.4 %) male. Compared with population prevalences, significant levels of Endocrine disorders were found in our study cohort. Sixty-six patients (81 shoulders, 62 female (93.9 %), 4 male (6.1 %), mean age 50.3 years) with associated Endocrine Disease were compared with 36 patients (44 shoulders, 11 female (30.6 %), 25 male (69.4 %), mean age 52.4 years) without Endocrine Disease. The Endocrine cohort were significantly younger than the non-Endocrine cohort when symptoms started (mean 40.9 years and 46.9 years respectively, p=0.0026), had significantly longer natural histories (mean 79.7 months compared with 47.1 months, p=0.0015) and a significantly higher proportion underwent opera...
-
calcific tendinitis natural history and association with Endocrine disorders
Journal of Shoulder and Elbow Surgery, 2007Co-Authors: Paul Harvie, T C B Pollard, Andrew CarrAbstract:A retrospective, observational cohort study of 102 consecutive patients (125 shoulders) with calcific tendinitis is presented. Of the patients, 73 (71.6%) were women and 29 (28.4%) were men. Compared with population prevalences, significant levels of Endocrine disorders were found. We compared 66 patients (62 women [93.9%] and 4 men [6.1%]; mean age, 50.3 years) (81 shoulders) with associated Endocrine Disease with 36 patients (11 women [30.6%] and 25 men [69.4%]); mean age, 52.4 years) (44 shoulders) without Endocrine Disease. The Endocrine cohort was significantly younger than the non-Endocrine cohort when symptoms started (mean, 40.9 years and 46.9 years, respectively), had significantly longer natural histories (mean, 79.7 months compared with 47.1 months), and had a significantly higher proportion who underwent operative treatment (46.9% compared with 22.7%). Disorders of thyroid and estrogen metabolism may contribute to calcific tendinitis etiology. Classifying calcific tendinitis into type I (idiopathic) and type II (secondary or Endocrine-related) aids prognosis and management.
-
calcific tendinitis natural history and association with Endocrine disorders
Journal of Bone and Joint Surgery-british Volume, 2005Co-Authors: Paul Harvie, T C B Pollard, Andrew CarrAbstract:The purpose of this study was to investigate the association of Endocrine Disease with calcific tendinitis and the effects that such Disease has on its natural history. A retrospective observational cohort study of 102 consecutive patients (125 shoulders) with calcific tendinitis is presented. Seventy-three (71.6 %) female, 29 (28.4 %) male. Compared with population prevalences, significant levels of Endocrine disorders were found in our study cohort. Sixty-six patients (81 shoulders, 62 female (93.9 %), 4 male (6.1 %), mean age 50.3 years) with associated Endocrine Disease were compared with 36 patients (44 shoulders, 11 female (30.6 %), 25 male (69.4 %), mean age 52.4 years) without Endocrine Disease. The Endocrine cohort were significantly younger than the non-Endocrine cohort when symptoms started (mean 40.9 years and 46.9 years respectively, p=0.0026), had significantly longer natural histories (mean 79.7 months compared with 47.1 months, p=0.0015) and a significantly higher proportion underwent operative treatment (46.9 % compared with 22.7 %, p=0.0014). Disorders of thyroid and oestrogen metabolism may contribute to calcific tendinitis aetiology. Classifying calcific tendinitis into Type I idiopathic and Type II secondary or Endocrine-related aids prognosis and management.
John Wass - One of the best experts on this subject based on the ideXlab platform.
-
management of Endocrine Disease pituitary tumour apoplexy
European Journal of Endocrinology, 2015Co-Authors: Cristina Capatina, Warrick J. Inder, Niki Karavitaki, John WassAbstract:Pituitary tumour apoplexy (PA) is a rare clinical syndrome that occurs as a result of acute haemorrhage and/or infarction within a frequently undiagnosed pituitary tumour. The sudden enlargement of the pituitary mass undergoing PA is responsible for a wide range of acute symptoms/signs (severe headache, visual loss, diplopia, hypopituitarism, impaired consciousness) which, together with the radiological evidence of a pituitary lesion, establish the diagnosis. The optimal care of PA requires involvement of a multidisciplinary team including endocrinologist, neurosurgeon, neuroophthalmologist and the management strategy that depends on the clinical manifestations, as well as the presence of co-morbidities. Prompt surgical decompression is initially indicated in cases with severe or progressive impairment of the visual acuity or the visual fields or with altered mental state and leads to visual and neurological recovery in most of the patients. The patients with mild, stable clinical picture (including those with isolated ocular palsies) can be managed conservatively (support of fluid and electrolyte balance and stress doses of steroids in most cases) with favourable visual and neurological outcome. Frequent reassessment is mandatory because the clinical course can be unpredictable; if progression of symptoms occurs, later elective surgery is indicated and is beneficial, especially in terms of visual outcome. The endocrinological outcome is less favourable, irrespective of the treatment option, with many patients remaining on long-term replacement therapy. Despite the above guidelines, clear proof of optimal outcomes in the form of randomised controlled trials is lacking. Regrowth of the pituitary tumour years after a PA episode is possible and patients require long-term surveillance.
Albert Beckers - One of the best experts on this subject based on the ideXlab platform.
-
management of Endocrine Disease pituitary incidentaloma neuroradiological assessment and differential diagnosis
European Journal of Endocrinology, 2016Co-Authors: Vladimir Vasilev, Iulia Potorac, S Zacharieva, Adrian Daly, Liliya Rostomyan, Jean-françois Bonneville, Albert BeckersAbstract:: Pituitary incidentalomas are a by-product of modern imaging technology. The term 'incidentaloma' is neither a distinct diagnosis nor a pathological entity. Rather, it is a collective designation for different entities that are discovered fortuitously, requiring a working diagnosis based on the input of the radiologist, endocrinologist and often a neurosurgeon. In addition to pathological conditions affecting the pituitary gland, a thorough knowledge of the radiological characteristics of normal variants and technical artifacts is required to arrive at an accurate differential diagnosis. After careful radiological and hormonal evaluation, the vast majority of pituitary incidentalomas turn out to be non-functioning pituitary microadenomas and Rathke's cleft cysts (RCCs). Based on the low growth potential of non-functioning pituitary microadenomas and RCCs, periodic MRI surveillance is currently considered the optimal management strategy. Stricter follow-up is required for macroadenomas, as increases in size occur more frequently.
-
cabergoline and the risk of valvular lesions in Endocrine Disease
European Journal of Endocrinology, 2008Co-Authors: Patrizio Lancellotti, Adrian Daly, Elena Livadariu, Muriel Markov, Mariacristina Burlacu, Daniela Betea, Luc Pierard, Albert BeckersAbstract:Aims: The cardiac valvular risk associated with lower exposure to cabergoline in common Endocrine conditions such as hyperprolactinemia is unknown. Methods and results: We performed a cross-sectional, case–control echocardiographic study to assess the valvular status in 102 subjects receiving cabergoline for Endocrine disorders and 51 matched control subjects. Cabergoline treatment ranged from 12 to 228 months, with a cumulative dose of 18–1718 mg. Valvular regurgitation was equally prevalent in both groups and was almost exclusively mild. Two cabergoline-treated subjects had moderate mitral regurgitation; there was no relationship between cabergoline dose and the presence or severity of mitral valve regurgitation (PZNS). Mitral valve tenting area was significantly greater in the cabergoline group when compared with the control subjects (PZ0.03). Mitral valve leaflet thickening was observed in 5.9% of cabergoline-treated subjects; no relationship with the cumulative cabergoline dose was found. No patient had aortic or tricuspid valvular restriction. Conclusion: No significantly increased risk of clinically relevant cardiac valve disorders was found in subjects treated with long-term cabergoline therapy at the doses used in Endocrine practice. While exposure to cabergoline appears to be safe during low-dose long-term therapy, an association with subclinical changes in mitral valve geometry cannot be completely excluded.
Niki Karavitaki - One of the best experts on this subject based on the ideXlab platform.
-
therapy of Endocrine Disease surgery in microprolactinomas effectiveness and risks based on contemporary literature
European Journal of Endocrinology, 2016Co-Authors: Metaxia Tampourlou, Raluca Trifanescu, Alessandro Paluzzi, Shahzada Ahmed, Niki KaravitakiAbstract:Microprolactinomas are the most common pituitary adenomas. In symptomatic patients, dopamine agonists are the first-line treatment of choice; when cabergoline is used, biochemical control rates between 85 and 93% have been reported. Long-term treatment is needed in most of the cases with compliance, patient convenience, and potential adverse effects representing areas requiring attention. Based on the literature published in the past 15 years, transsphenoidal surgery can lead to normal prolactin in the postoperative period in usually 71-100% of the cases with very low postoperative complication rates. Surgical expertise is the major determinant of the outcomes, and it may be a cost-effective option in young patients with life expectancy greater than 10 years (provided it is performed by experienced surgeons at high volume centers with confirmed optimal outcomes). Larger series of patients with adequate follow-up could further validate the place of transsphenoidal surgery (particularly through the endoscopic approach for which long-term results are currently limited) in the management algorithm of patients with microprolactinoma.
-
management of Endocrine Disease pituitary tumour apoplexy
European Journal of Endocrinology, 2015Co-Authors: Cristina Capatina, Warrick J. Inder, Niki Karavitaki, John WassAbstract:Pituitary tumour apoplexy (PA) is a rare clinical syndrome that occurs as a result of acute haemorrhage and/or infarction within a frequently undiagnosed pituitary tumour. The sudden enlargement of the pituitary mass undergoing PA is responsible for a wide range of acute symptoms/signs (severe headache, visual loss, diplopia, hypopituitarism, impaired consciousness) which, together with the radiological evidence of a pituitary lesion, establish the diagnosis. The optimal care of PA requires involvement of a multidisciplinary team including endocrinologist, neurosurgeon, neuroophthalmologist and the management strategy that depends on the clinical manifestations, as well as the presence of co-morbidities. Prompt surgical decompression is initially indicated in cases with severe or progressive impairment of the visual acuity or the visual fields or with altered mental state and leads to visual and neurological recovery in most of the patients. The patients with mild, stable clinical picture (including those with isolated ocular palsies) can be managed conservatively (support of fluid and electrolyte balance and stress doses of steroids in most cases) with favourable visual and neurological outcome. Frequent reassessment is mandatory because the clinical course can be unpredictable; if progression of symptoms occurs, later elective surgery is indicated and is beneficial, especially in terms of visual outcome. The endocrinological outcome is less favourable, irrespective of the treatment option, with many patients remaining on long-term replacement therapy. Despite the above guidelines, clear proof of optimal outcomes in the form of randomised controlled trials is lacking. Regrowth of the pituitary tumour years after a PA episode is possible and patients require long-term surveillance.